Generic competition · all medicines · read 12 November 2026
Is there a generic of Methocarbamol, and who makes it?
Methocarbamol appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 17 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.
Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.
- Methocarbamol appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 17 generic makers listed as marketed across them.
- 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
- Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.
Tablet, Oral
Four or more generic makers listed
Every brand product here is listed as discontinued. 9 generic makers with 20 generic products listed as marketed; the first generic approval is dated 22 January 1982.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Prinston Pharmaceutical Inc | not dated | 2 |
| Oxford Pharmaceuticals Llc | 29 January 2003 | 2 |
| Hetero Labs Ltd Unit Iii | 6 November 2009 | 2 |
| Bostal Llc | 21 October 2011 | 3 |
| Pharmobedient Consulting Llc | 8 February 2017 | 3 |
| Regcon Holdings Llc | 21 July 2017 | 2 |
| Granules India Ltd | 7 May 2018 | 2 |
| Aurobindo Pharma Ltd | 12 August 2020 | 2 |
| Pharmazone | 30 April 2021 | 2 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Solution, Im-Iv
Four or more generic makers listed
Brand listed as marketed: Robaxin. 8 generic makers with 8 generic products listed as marketed; the first generic approval is dated 5 December 2014.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Eugia Pharma Specialities Ltd | 27 May 2016 | 1 |
| Monterey Pharmaceuticals Llc | 27 October 2016 | 1 |
| Hainan Poly Pharm Co Ltd | 19 January 2017 | 1 |
| American Regent Inc | 22 June 2017 | 1 |
| Sagent Pharmaceuticals Inc | 18 July 2017 | 1 |
| Somerset Therapeutics Llc | 31 July 2017 | 1 |
| Fresenius Kabi Usa Llc | 17 April 2018 | 1 |
| Gland Pharma Ltd | 26 October 2018 | 1 |
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Injectable, Injection
Nothing listed as marketed
No brand application is listed. No generic is listed as marketed (2 generic products listed as discontinued).
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Suspension, Oral
Brand listed, no generic listed as marketed
Brand listed as marketed: Atmeksi. No generic is listed as marketed.
Patents and exclusivities still listed
- 9 October 2044Patent 12390439 drug product
US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.
Where can you go from this result?
Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.